Lupin's Joint Airways Initiative surpasses 10,000 patients

Lupin, Cost Plus Drug and COPD Foundation to expand access to medication for COPD patients

This collaboration marks a significant milestone in countering the disease burden by enhancing access to products for patients in the US

Lupin receives USFDA approval for Pirfenidone Capsules

Pirfenidone Capsules had estimated annual sales of USD 95 million in the US

Lupin launches propranolol capsules to improve heart health in Canada

Propranolol LA is a generic equivalent of Inderal LA

Lupin receives approval from USFDA for Pirfenidone Tablets

This product will be manufactured at Lupin's Pithampur facility in India

Lupin receives approval from USFDA for Bromfenac Ophthalmic

Bromfenac Ophthalmic Solution 0.09% (RLD Bromday) had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT June 2023).

Lupin acquires Boehringer Ingelheim's brands Ondero and Ondero Met to expand diabetes portfolio in India

This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes

Lupin launches ‘Jeet’ to raise awareness of cardiovascular disease among patients

Jeet will be a trusted partner in cardiovascular care

Lupin Launches Tiotropium Dry Powder for Inhaler for COPD in US

Lupin actively contributes to alleviating the burden of COPD for patients across the nation

Lupin's Mandideep Unit-2 facility completes USFDA inspection with no observations

The inspection was conducted from August 7 to August 11, 2023 and concluded without any observations.